Mechanisms of allelic and clinical heterogeneity of lamin A/C phenotypes

Abstract

Mutations in the lamin A/C ( LMNA) gene cause a broad range of clinical syndromes that show tissue-restricted abnormalities of post mitotic tissues, such as muscle, nerve, heart, and adipose tissue. Mutations in other nuclear envelope proteins cause clinically overlapping disorders. The majority of mutations are dominant single amino acid changes (toxic protein produced by the single mutant gene), and patients are heterozygous with both normal and abnormal proteins. Experimental support has been provided for different models of cellular pathogenesis in nuclear envelope diseases, including changes in heterochromatin formation at the nuclear membrane (epigenomics), changes in the timing of steps during terminal differentiation of cells, and structural abnormalities of the nuclear membrane. These models are not mutually exclusive and may be important in different cells at different times of development. Recent experiments using fusion proteins of normal and mutant lamin A/C proteins fused to a bacterial adenine methyltransferase (DamID) provided compelling evidence of mutation-specific perturbation of epigenomic imprinting during terminal differentiation. These gain-of-function properties include lineage-specific ineffective genomic silencing during exit from the cell cycle (heterochromatinization), as well as promiscuous initiation of silencing at incorrect places in the genome. To date, these findings have been limited to a few muscular dystrophy and lipodystrophy LMNA mutations but seem shared with a distinct nuclear envelope disease, emerin-deficient muscular dystrophy. The dominant-negative structural model and gain-of-function epigenomic models for distinct LMNA mutations are not mutually exclusive, and it is likely that both models contribute to aspects of the many complex clinical phenotypes observed.

Keywords: chromatin remodeling; epigenetics; laminopathies; muscle disease.

Fig. 1.

Schematic representation of epigenomic and structural laminopathies models. Top: peripheral chromatin remodeling during myogenic induction where pluripotency and cell cycle loci undergo heterochromatinization process required for cell cycle exit and terminal differentiation into myotubes. Bottom: impairments due to loss of lamin A/C and emerin. During myogenic differentiation, defects in nucleoskeletal proteins lamin A/C and emerin not only impair the structural integrity of the cell (structural model) but also impair peripheral chromatin remodeling (epigenomic model), which leads to inadequate and prolonged expression of pluripotency and cell genes.